February 8, 2010 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, February 11th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and February earnings reports. Glatfelter (NYSE: GLT), ARIAD Pharmaceuticals (NASDAQ: ARIA), KBW Inc. (NYSE: KBW), TradeStation Group (NASDAQ: TRAD), The Phoenix Companies (NYSE: PNX) and ZymoGenetics (NASDAQ: ZGEN) are all expected to be lower after their earnings are released Thursday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go lower after earnings are released Thursday:

Symbol Company # of Reports Quarter Release Time

GLT Glatfelter 12 quarters Q4 Before

ARIA ARIAD Pharmaceuticals February earnings Q4 Before

KBW KBW, Inc. 12 quarters Q4 Before

TRAD TradeStation Group 12 quarters Q4 Before

PNX The Phoenix Companies 12 quarters Q4 Before

ZGEN ZymoGenetics, Inc. February earnings Q4 After


Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company.

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

P.H. Glatfelter Company (NYSE: GLT), together with its subsidiaries, manufactures specialty papers and engineered products in the United States and internationally. It offers book publishing papers for the production of hardbound books and other book publishing needs; carbonless and forms papers for credit card receipts, multi-part forms, security papers, and other end-user applications; envelope and converting papers for the direct mail market, shopping bags, and other converting applications; and engineered products for digital imaging, transfer, casting, release, postal, and playing card applications. The companya™s products include food and beverage paper used for tea bags and coffee pods/pads and filters; composite laminate papers used in production of decorative laminates for furniture and flooring; and metallized products used in the labeling of beer bottles, inner liners, gift wrap, self-adhesive labels, and other consumer products applications, as well as a line of paper products used in batteries, medical masks, and other engineered applications. It serves customers in various markets, including book publishing, carbonless and forms, envelope and converting, engineered products, food and beverage, and composite laminates markets. The company sells its products directly, as well as through wholesale paper merchants, brokers, and agents primarily in the United States, Germany, and the United Kingdom. P.H. Glatfelter Company was founded in 1864 and is headquartered in York, Pennsylvania.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States and Europe. Its product candidates include deforolimus, a potent mTOR inhibitor for the treatment of solid tumors, including sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, leukemias, and lymphomas; and AP24534, a multi-targeted kinase inhibitor for the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and other hematological cancers. ARIAD conducts Phase 3 clinical trials of oral deforolimus in patients with metastatic soft-tissue and bone sarcomas; Phase 2 clinical trials in patients with endometrial, breast, and prostate cancers; and Phase 1 studies of deforolimus in combination with other agents, as well as Phase 1 clinical trials of AP24534 in patients with refractory CML, AML, and other hematological malignancies. Its drug discovery programs are centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. In addition, the company licenses NF-kB cell-signaling technology and treatment methods to pharmaceutical and biotechnology companies conducting research to discover and develop drugs that modulate NF-kB cell-signaling and/or marketing such drugs; and ARGENT cell-signaling regulation technologies to pharmaceutical and biotechnology companies to develop and commercialize therapeutic products and to conduct drug discovery research. It has a collaboration agreement with Merck & Co., Inc. to develop and commercialize deforolimus; and license agreements with Medinol and ICON to develop and commercialize deforolimus-eluting stents and other medical devices to prevent restenosis, or reblockage of injured vessels following interventions, in which stents are used in conjunction with balloon angioplasty. The company was founded in 1991 and is based in Cambridge, Massachusetts.

KBW, Inc. (NYSE: KBW), through its subsidiaries, operates in the financial services industry in the United States and Europe. The company provides various investment banking services, including mergers and acquisitions, strategic advisory services, capital raising services, equity and fixed income securities offerings, and mutual thrift conversions, as well as equity and fixed income sales and trading services. In addition, the company offers research services comprising fundamental and objective analysis that identifies investment opportunities and assists investors to make investment decisions, as well as provides asset management services, including investment management and other advisory services to institutional clients, private high net worth clients, and various investment vehicles. It serves bank and thrift holding companies, banks and thrifts, insurance companies, broker-dealers, mortgage banks, asset management companies, real estate investment trusts, consumer and specialty finance firms, financial processing companies, and securities exchanges. The company was founded in 1962 and is headquartered in New York, New York.

TradeStation Group, Inc. (NASDAQ: TRAD) operates as an online broker-dealer, an introducing broker, a futures commission merchant, and a trading technology company. Its product/service includes TradeStation, an electronic trading platform that enables traders to test and automate technical and fundamental trading strategies across various asset classes. The company also offers online brokerage services covering equities, equity and index options, financial and commodities futures, futures options, and spot forex transactions. It also provides TradeStation electronic subscription service, which includes trading features and functions, streaming charts and quotes, streaming news, analytical charting, and various other features included in the TradeStation electronic trading platform other than trade order placement, and other trading or brokerage-related features or services. TradeStation Group serves the active trader and institutional trader markets. The company has strategic relationships with J.P. Morgan Clearing Corp.; R.J. Oa™Brien & Associates, Inc.; and GAIN Capital Group, Inc. The company was founded in 1982 and is headquartered in Plantation, Florida.

The Phoenix Companies, Inc. (NYSE: PNX), through its subsidiaries, provides life insurance and annuity products in the United States. The companya™s life insurance products include universal life, variable universal life, and term life products. It offers single life, first-to-die, and second-to-die insurance products. The Phoenix annuity products comprise variable annuities and immediate annuities. It also offers private placement life and annuity products, which are individually customized life and annuity offerings. The company also provides underwriting and mortality management, as well as distribution and support services. It markets its products through national and regional broker-dealers, financial planning firms, advisor groups, insurance companies, brokerage general agencies, and banks. The company was founded in 1851 and is headquartered in Hartford, Connecticut.

ZymoGenetics, Inc. (NASDAQ: ZGEN), a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent used for the control of moderate bleeding during surgical procedures. The companya™s product candidates in clinical development stages include PEG-IFN-l, a pegylated version of the IFN-l1 protein, which is in Phase Ib clinical trials for the treatment of viral infections and autoimmune diseases; IL-21 for the treatment of metastatic melanoma and metastatic renal cell carcinoma; IL-21 monoclonal antibody (mAb) to treat inflammatory diseases; and IL-31 mAb for the treatment of atopic dermatitis and inflammatory diseases. Its out-licensed product candidates include atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; Augment Bone Graft for orthopedic fracture and other bone defects; rFactor XIII for congenital factor XIII deficiency, cardiac surgery, and cancer related bleeding; Fibroblast growth factor-18 for osteoarthritis; IL-17 receptor C for inflammatory diseases; and IL-20 and IL-22 receptor subunit alpha for psoriasis. The company also offers out-licensed commercial products comprising Novolin and insulin analogs for diabetes; NovoSeven for the treatment of hemophilia; Regranex for wound healing; GEM 21S for periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor for treatment of myocardial infarction. ZymoGenetics has collaboration agreements with Bayer Schering Pharma AG; Bristol-Myers Squibb Company; and Merck Serono S.A. The company was founded in 1981 and is headquartered in Seattle, Washington.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.


About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha™s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact:
Thomas Ronk, CEO
www.squeezetrigger.com
+1-800-715-9999
Tom@squeezetrigger.com


SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

_{Content Managed by News-Articles.NET}